drugset / Trial / NCT01080209

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

NCT01080209

Phase 2 Completed 215 enrolled Allergan
Non-randomizedSingle-groupSingle-blind

Summary

This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.

Timeline

Start
2010-02
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 50 ug Intravitreal
Subject Brimonidine Small molecule 100 ug Intravitreal
Subject Brimonidine Small molecule 200 ug Intravitreal
Subject Brimonidine Small molecule 400 ug Intravitreal

Indications

No indication recorded.